KDCXF yields 125.00% · PFE yields 6.13%● Live data
📍 KDCXF pulled ahead of the other in Year 1
Combined, KDCXF + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of KDCXF + PFE for your $10,000?
Kudelski SA develops and delivers a range of digital security solutions for digital television and interactive applications in Switzerland, the United States, France, the Netherlands, and internationally. It operates through four segments: Digital TV, Cybersecurity, Internet of Things (IoT), and Public Access. The Digital TV segment offers integrated solutions, including open conditional access solutions, which allow TV operators and content providers to operate various value-added pay-TV services on a secure platform, and middleware software solutions for set-top boxes and other consumer devices; and intellectual property consulting services. The Cybersecurity segment provides cybersecurity solutions to enterprises and public sector institutions, which include consulting, technology and resale services, managed security and custom developed proprietary products, and threat intelligence solutions that help organizations to build and run security programs. The IoT segment offers device security through identity authentication and firmware protection; data security to ensure the confidentiality, integrity, and authenticity of sensitive data; and access management and active security protections to enable secure processing, local decision making, and threat detection and response. The Public Access segment provides access control systems and ticketing services for ski lifts, car parks, stadiums, concert halls, and other events. The company also offers watermarking solutions; smartcards and digital TV sales and support services; research and development services; finance services; and research and development digital broadcasting solutions, as well as operates a travel agency. Kudelski SA was founded in 1951 and is headquartered in Cheseaux-sur-Lausanne, Switzerland.
Full KDCXF Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.